AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

NexImmune Management to Present at Upcoming Conferences

December 2, 2019

GAITHERSBURG, Md., Dec. 02, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive Officer, will be particpating and presenting a corporate update at the following conferences. A webcast of Wednesday’s presentation will be available on the Company’s website under the News & Events tab.

Piper Jaffray’s 31st Annual Healthcare Conference Tuesday, December 3rd, 3:50PM ET New York, NYEvercore’s 2nd Annual HealthCONx Conference Wednesday, December 4th, 3:50PM ET Boston, MA About NexImmune NexImmune is a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on the proprietary Artificial Immune Modulation (AIM) nanotechnology platform. The AIM platform enables the ability to expand multi-antigen specific T cells with enhanced anti-tumor properties without the need for genetic manipulation. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer and auto-immune diseases.The AIM platform is comprised of two core components: (1) a synthetic nanoparticle that functions as an artificial antigen presenting cell (aAPC) to prime and activate T cells directed at multiple tumor antigen targets across a broad range of both solid and hematologic malignancies; and (2) a proprietary T cell enrichment and expansion (E&E) process that controls ex vivo T cell proliferation and subtype differentiation. In preclinical experiments, the AIM system demonstrated the ability to enhance naturally occuring tumor cell recognition, engagement and signaling mechanisms that increased the anti-tumor potency, target specific killing and long-term durability of endogenous cytolytic T-cells. Utilizing natural target recognition and killing mechanisms may also reduce the potential for alloreactive toxicities observed with genetically engineered T cell therapies. The Company’s aAPCs have also demonstrated potential utility as both injectable and cellular therapeutic agents.For more information visit: www.neximmune.com

Contact

Chad Rubin Solebury Trout crubin@soleburytrout.com +1-646-378-2947